Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment
Glioblastoma remains the most common and aggressive primary brain tumor today. Because of the neuroanatomical location of glioblastoma, conventional chemotherapy and radiation therapy have limited efficacy in patients with these tumors. Over the past decade, antitumor immunotherapy has become widesp...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2021-06-01
|
| Series: | Медицинская иммунология |
| Subjects: | |
| Online Access: | https://www.mimmun.ru/mimmun/article/view/2111 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839571423964692480 |
|---|---|
| author | S. V. Timofeeva A. O. Sitkovskaya I. A. Novikova M. A. Ezhova E. P. Lysenko O. I. Kit |
| author_facet | S. V. Timofeeva A. O. Sitkovskaya I. A. Novikova M. A. Ezhova E. P. Lysenko O. I. Kit |
| author_sort | S. V. Timofeeva |
| collection | DOAJ |
| description | Glioblastoma remains the most common and aggressive primary brain tumor today. Because of the neuroanatomical location of glioblastoma, conventional chemotherapy and radiation therapy have limited efficacy in patients with these tumors. Over the past decade, antitumor immunotherapy has become widespread among modern therapeutic approaches. The importance of immunotherapeutic methods lies in their ability to increase the effectiveness of cancer treatment and prevent relapses by enhancing the systemic and local immune response against tumor cells.One of the most promising directions in modern immunotherapy is CAR-T therapy, or adoptive cell therapy using genetically modified T-lymphocytes. The functional advantage of CAR-T therapy is its ability to genetically modify lymphocytes, leading to their activation in vitro.This review examines the key principles of CAR-T therapy and analyzes the published results of clinical trials for the treatment of glioblastoma using several modifications of CAR-T cells. |
| format | Article |
| id | doaj-art-bc84923f84924863a08fac30e16a46d8 |
| institution | Matheson Library |
| issn | 1563-0625 2313-741X |
| language | Russian |
| publishDate | 2021-06-01 |
| publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| record_format | Article |
| series | Медицинская иммунология |
| spelling | doaj-art-bc84923f84924863a08fac30e16a46d82025-08-04T14:30:38ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2021-06-0123348349610.15789/1563-0625-RAI-21111400Recent achievements in CAR-T cell immunotherapy for glioblastoma treatmentS. V. Timofeeva0A. O. Sitkovskaya1I. A. Novikova2M. A. Ezhova3E. P. Lysenko4O. I. Kit5National Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyGlioblastoma remains the most common and aggressive primary brain tumor today. Because of the neuroanatomical location of glioblastoma, conventional chemotherapy and radiation therapy have limited efficacy in patients with these tumors. Over the past decade, antitumor immunotherapy has become widespread among modern therapeutic approaches. The importance of immunotherapeutic methods lies in their ability to increase the effectiveness of cancer treatment and prevent relapses by enhancing the systemic and local immune response against tumor cells.One of the most promising directions in modern immunotherapy is CAR-T therapy, or adoptive cell therapy using genetically modified T-lymphocytes. The functional advantage of CAR-T therapy is its ability to genetically modify lymphocytes, leading to their activation in vitro.This review examines the key principles of CAR-T therapy and analyzes the published results of clinical trials for the treatment of glioblastoma using several modifications of CAR-T cells.https://www.mimmun.ru/mimmun/article/view/2111car-t-терапияглиобластомаклинические испытанияil-13r α2her2egfrviii |
| spellingShingle | S. V. Timofeeva A. O. Sitkovskaya I. A. Novikova M. A. Ezhova E. P. Lysenko O. I. Kit Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment Медицинская иммунология car-t-терапия глиобластома клинические испытания il-13r α2 her2 egfrviii |
| title | Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment |
| title_full | Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment |
| title_fullStr | Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment |
| title_full_unstemmed | Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment |
| title_short | Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment |
| title_sort | recent achievements in car t cell immunotherapy for glioblastoma treatment |
| topic | car-t-терапия глиобластома клинические испытания il-13r α2 her2 egfrviii |
| url | https://www.mimmun.ru/mimmun/article/view/2111 |
| work_keys_str_mv | AT svtimofeeva recentachievementsincartcellimmunotherapyforglioblastomatreatment AT aositkovskaya recentachievementsincartcellimmunotherapyforglioblastomatreatment AT ianovikova recentachievementsincartcellimmunotherapyforglioblastomatreatment AT maezhova recentachievementsincartcellimmunotherapyforglioblastomatreatment AT eplysenko recentachievementsincartcellimmunotherapyforglioblastomatreatment AT oikit recentachievementsincartcellimmunotherapyforglioblastomatreatment |